Bata M S, Al-Ramahi M, Salhab A S, Gharaibeh M N, Schwartz Jill
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Jordan, Amman, Jordan.
J Clin Pharmacol. 2006 Aug;46(8):925-32. doi: 10.1177/0091270006289483.
This study aimed to assess the effect of meloxicam on female ovulation. Twenty consented fertile females were monitored for 4 menstrual cycles: a baseline cycle, 2 treatment cycles, and a washout cycle between treatment cycles. In the first cycle visit, transvaginal ultrasound was performed, a blood sample for progesterone and meloxicam analysis was withdrawn, and volunteers were given a luteinizing hormone (LH) urine test kit and meloxicam or placebo. Volunteers started the treatment on the following day and asked to return the day the LH kit was positive to detect the dominant follicle. At subsequent visits, transvaginal ultrasound and progesterone and meloxicam levels were investigated. Compared to placebo, a 5-day delay in follicle rupture, a 55.7% increase in the mean maximum follicle diameter, and 33.5% decrease of plasma progesterone level were observed in the meloxicam-treated group. Such demonstrated meloxicam effects were reversed in participants who were randomized to meloxicam first and then placebo. Only minor side effects were reported by volunteers during the course of treatment. It is concluded that meloxicam resulted in a reversible delay of ovulation, an increase in follicular diameter, and a decrease in plasma progesterone level.
本研究旨在评估美洛昔康对女性排卵的影响。对20名同意参与研究的育龄女性进行了4个月经周期的监测：一个基线周期、2个治疗周期以及治疗周期之间的洗脱期。在首次周期访视时，进行经阴道超声检查，采集血液样本用于检测孕酮和美洛昔康，为志愿者提供促黄体生成素（LH）尿液检测试剂盒以及美洛昔康或安慰剂。志愿者于次日开始治疗，并被要求在LH试剂盒检测结果呈阳性时返回，以检测优势卵泡。在后续访视中，进行经阴道超声检查，并检测孕酮和美洛昔康水平。与安慰剂组相比，美洛昔康治疗组的卵泡破裂延迟了5天，平均最大卵泡直径增加了55.7%，血浆孕酮水平降低了33.5%。在先随机接受美洛昔康治疗、后接受安慰剂治疗的参与者中，上述美洛昔康的作用得到了逆转。志愿者在治疗过程中仅报告了轻微的副作用。研究得出结论，美洛昔康导致排卵出现可逆性延迟、卵泡直径增加以及血浆孕酮水平降低。
